Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-03-01

AUTHORS

Chiara Di Loreto, Viviana Minarelli, Giovanni Nasini, Roberto Norgiolini, Paola Del Sindaco

ABSTRACT

IntroductionTo complement results of the SUSTAIN program, this study assessed effectiveness and safety of once weekly subcutaneous semaglutide in people with type 2 diabetes (T2D) managed under routine care.MethodsThis was a multicenter, observational, retrospective study including all patients treated with semaglutide. Changes in clinical outcomes from baseline to 6 and 12 months were assessed in patients who were glucagon-like peptide receptor agonist (GLP-1RA) naïve or switching from another GLP-1RA. Discontinuation rate was assessed.ResultsOverall, 216 patients (mean age 64 years, 65.7% men) were evaluated: 135 (61.5%) naïve and 81 (38.5%) switchers from another GLP-1RA. In the naïve cohort, after 6 months from semaglutide initiation, levels of HbA1c significantly decreased by − 1.31% (p < 0.0001). All obesity indices improved, with mean reductions in body weight of − 3.92 kg, in BMI of − 1.43 kg/m2, and in waist circumference of − 5.03 cm. In the switcher cohort, statistically significant improvements in HbA1c (− 0.78%), body weight (− 2.64 kg), and waist circumference (− 3.03 cm) were obtained after 6 months. Reductions were sustained after 12 months in both cohorts (mean semaglutide dose: 0.86 mg in naïve and 0.96 mg in switcher cohort). Blood pressure and lipid profile mean levels decreased after 12 months from semaglutide initiation in both cohorts. No severe hypoglycemia occurred; 6.5% of patients discontinued semaglutide (2.8% due to gastrointestinal side effects).ConclusionEffectiveness and tolerability of semaglutide have been confirmed in the real world irrespective of diabetes duration and severity. As expected, more marked reductions in HbA1c and obesity indices were obtained in naïve patients, but it is noteworthy that relevant improvements were also obtained in patients already treated with GLP-1RAs. More... »

PAGES

551-567

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01218-y

DOI

http://dx.doi.org/10.1007/s13300-022-01218-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1145925452

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35230650


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Diabetes Clinic, USL Umbria 1, Perugia Territorial Health Structure, Perugia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Diabetes Clinic, USL Umbria 1, Perugia Territorial Health Structure, Perugia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Loreto", 
        "givenName": "Chiara", 
        "id": "sg:person.013423740504.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013423740504.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Clinic, USL Umbria 1, Citt\u00e0 di Castello Hospital, Citt\u00e0 di Castello, Italy", 
          "id": "http://www.grid.ac/institutes/grid.502754.1", 
          "name": [
            "Diabetes Clinic, USL Umbria 1, Citt\u00e0 di Castello Hospital, Citt\u00e0 di Castello, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Minarelli", 
        "givenName": "Viviana", 
        "id": "sg:person.01121135113.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121135113.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Clinic, USL Umbria 1, Castiglione del Lago Hospital District, Castiglione del Lago, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Diabetes Clinic, USL Umbria 1, Castiglione del Lago Hospital District, Castiglione del Lago, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nasini", 
        "givenName": "Giovanni", 
        "id": "sg:person.07745622554.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07745622554.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Clinic, USL Umbria 1, Citt\u00e0 di Castello Hospital, Citt\u00e0 di Castello, Italy", 
          "id": "http://www.grid.ac/institutes/grid.502754.1", 
          "name": [
            "Diabetes Clinic, USL Umbria 1, Citt\u00e0 di Castello Hospital, Citt\u00e0 di Castello, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Norgiolini", 
        "givenName": "Roberto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Clinic, USL Umbria 1, Perugia Territorial Health Structure, Perugia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Diabetes Clinic, USL Umbria 1, Perugia Territorial Health Structure, Perugia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Del Sindaco", 
        "givenName": "Paola", 
        "id": "sg:person.011233417104.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011233417104.69"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-020-00984-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134130078", 
          "https://doi.org/10.1007/s13300-020-00984-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-021-01010-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1135420761", 
          "https://doi.org/10.1007/s13300-021-01010-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-020-00894-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1129709395", 
          "https://doi.org/10.1007/s13300-020-00894-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-021-01015-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1135271828", 
          "https://doi.org/10.1007/s13300-021-01015-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-021-01053-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1137050437", 
          "https://doi.org/10.1007/s13300-021-01053-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-03-01", 
    "datePublishedReg": "2022-03-01", 
    "description": "IntroductionTo complement results of the SUSTAIN program, this study assessed effectiveness and safety of once weekly subcutaneous semaglutide in people with type 2 diabetes (T2D) managed under routine care.MethodsThis was a multicenter, observational, retrospective study including all patients treated with semaglutide. Changes in clinical outcomes from baseline to 6 and 12\u00a0months were assessed in patients who were glucagon-like peptide receptor agonist (GLP-1RA) na\u00efve or switching from another GLP-1RA. Discontinuation rate was assessed.ResultsOverall, 216 patients (mean age 64\u00a0years, 65.7% men) were evaluated: 135 (61.5%) na\u00efve and 81 (38.5%) switchers from another GLP-1RA. In the na\u00efve cohort, after 6\u00a0months from semaglutide initiation, levels of HbA1c significantly decreased by \u2212 1.31% (p\u2009<\u20090.0001). All obesity indices improved, with mean reductions in body weight of \u2212 3.92\u00a0kg, in BMI of \u2212 1.43\u00a0kg/m2, and in waist circumference of \u2212 5.03\u00a0cm. In the switcher cohort, statistically significant improvements in HbA1c (\u2212 0.78%), body weight (\u2212 2.64\u00a0kg), and waist circumference (\u2212 3.03\u00a0cm) were obtained after 6\u00a0months. Reductions were sustained after 12\u00a0months in both cohorts (mean semaglutide dose: 0.86\u00a0mg in na\u00efve and 0.96\u00a0mg in switcher cohort). Blood pressure and lipid profile mean levels decreased after 12\u00a0months from semaglutide initiation in both cohorts. No severe hypoglycemia occurred; 6.5% of patients discontinued semaglutide (2.8% due to gastrointestinal side effects).ConclusionEffectiveness and tolerability of semaglutide have been confirmed in the real world irrespective of diabetes duration and severity. As expected, more marked reductions in HbA1c and obesity indices were obtained in na\u00efve patients, but it is noteworthy that relevant improvements were also obtained in patients already treated with GLP-1RAs.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01218-y", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "GLP-1RAs", 
      "obesity indices", 
      "waist circumference", 
      "body weight", 
      "glucagon-like peptide receptor agonists", 
      "weekly subcutaneous semaglutide", 
      "retrospective observational study", 
      "type 2 diabetes", 
      "peptide receptor agonists", 
      "subcutaneous semaglutide", 
      "weekly semaglutide", 
      "diabetes duration", 
      "na\u00efve patients", 
      "discontinuation rates", 
      "routine care", 
      "blood pressure", 
      "severe hypoglycemia", 
      "clinical outcomes", 
      "retrospective study", 
      "receptor agonist", 
      "na\u00efve cohort", 
      "observational study", 
      "mean reduction", 
      "patients", 
      "type 2", 
      "cohort", 
      "marked reduction", 
      "relevant improvement", 
      "months", 
      "mean levels", 
      "HbA1c", 
      "sustain programs", 
      "semaglutide", 
      "na\u00efve", 
      "circumference", 
      "significant improvement", 
      "multicenter", 
      "tolerability", 
      "MethodsThis", 
      "BMI", 
      "hypoglycemia", 
      "diabetes", 
      "ResultsOverall", 
      "agonists", 
      "initiation", 
      "baseline", 
      "severity", 
      "care", 
      "study", 
      "index", 
      "outcomes", 
      "levels", 
      "reduction", 
      "weight", 
      "duration", 
      "complement results", 
      "safety", 
      "improvement", 
      "people", 
      "effectiveness", 
      "rate", 
      "switchers", 
      "m2", 
      "changes", 
      "pressure", 
      "results", 
      "program", 
      "Umbria", 
      "world", 
      "real world"
    ], 
    "name": "Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Na\u00efve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria", 
    "pagination": "551-567", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1145925452"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01218-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35230650"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01218-y", 
      "https://app.dimensions.ai/details/publication/pub.1145925452"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_951.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01218-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01218-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01218-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01218-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01218-y'


 

This table displays all metadata directly associated to this object as RDF triples.

183 TRIPLES      21 PREDICATES      100 URIs      87 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01218-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N9fb1e70201554ecebff1ba89d155bff8
4 schema:citation sg:pub.10.1007/s13300-020-00894-y
5 sg:pub.10.1007/s13300-020-00984-x
6 sg:pub.10.1007/s13300-021-01010-4
7 sg:pub.10.1007/s13300-021-01015-z
8 sg:pub.10.1007/s13300-021-01053-7
9 schema:datePublished 2022-03-01
10 schema:datePublishedReg 2022-03-01
11 schema:description IntroductionTo complement results of the SUSTAIN program, this study assessed effectiveness and safety of once weekly subcutaneous semaglutide in people with type 2 diabetes (T2D) managed under routine care.MethodsThis was a multicenter, observational, retrospective study including all patients treated with semaglutide. Changes in clinical outcomes from baseline to 6 and 12 months were assessed in patients who were glucagon-like peptide receptor agonist (GLP-1RA) naïve or switching from another GLP-1RA. Discontinuation rate was assessed.ResultsOverall, 216 patients (mean age 64 years, 65.7% men) were evaluated: 135 (61.5%) naïve and 81 (38.5%) switchers from another GLP-1RA. In the naïve cohort, after 6 months from semaglutide initiation, levels of HbA1c significantly decreased by − 1.31% (p < 0.0001). All obesity indices improved, with mean reductions in body weight of − 3.92 kg, in BMI of − 1.43 kg/m2, and in waist circumference of − 5.03 cm. In the switcher cohort, statistically significant improvements in HbA1c (− 0.78%), body weight (− 2.64 kg), and waist circumference (− 3.03 cm) were obtained after 6 months. Reductions were sustained after 12 months in both cohorts (mean semaglutide dose: 0.86 mg in naïve and 0.96 mg in switcher cohort). Blood pressure and lipid profile mean levels decreased after 12 months from semaglutide initiation in both cohorts. No severe hypoglycemia occurred; 6.5% of patients discontinued semaglutide (2.8% due to gastrointestinal side effects).ConclusionEffectiveness and tolerability of semaglutide have been confirmed in the real world irrespective of diabetes duration and severity. As expected, more marked reductions in HbA1c and obesity indices were obtained in naïve patients, but it is noteworthy that relevant improvements were also obtained in patients already treated with GLP-1RAs.
12 schema:genre article
13 schema:isAccessibleForFree true
14 schema:isPartOf N158351eda93644699f9dae0898fbe490
15 N2d2ece0cf90e49c0b4bd2925876105c8
16 sg:journal.1044057
17 schema:keywords BMI
18 GLP-1RAs
19 HbA1c
20 MethodsThis
21 ResultsOverall
22 Umbria
23 agonists
24 baseline
25 blood pressure
26 body weight
27 care
28 changes
29 circumference
30 clinical outcomes
31 cohort
32 complement results
33 diabetes
34 diabetes duration
35 discontinuation rates
36 duration
37 effectiveness
38 glucagon-like peptide receptor agonists
39 hypoglycemia
40 improvement
41 index
42 initiation
43 levels
44 m2
45 marked reduction
46 mean levels
47 mean reduction
48 months
49 multicenter
50 naïve
51 naïve cohort
52 naïve patients
53 obesity indices
54 observational study
55 outcomes
56 patients
57 people
58 peptide receptor agonists
59 pressure
60 program
61 rate
62 real world
63 receptor agonist
64 reduction
65 relevant improvement
66 results
67 retrospective observational study
68 retrospective study
69 routine care
70 safety
71 semaglutide
72 severe hypoglycemia
73 severity
74 significant improvement
75 study
76 subcutaneous semaglutide
77 sustain programs
78 switchers
79 tolerability
80 type 2
81 type 2 diabetes
82 waist circumference
83 weekly semaglutide
84 weekly subcutaneous semaglutide
85 weight
86 world
87 schema:name Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
88 schema:pagination 551-567
89 schema:productId Nb5095dada8554f72a9360b4c33765fb4
90 Nd895bd8986df45fe8a047e6523e95f8c
91 Nf64eb2f1642645df878c19bde04bbb38
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145925452
93 https://doi.org/10.1007/s13300-022-01218-y
94 schema:sdDatePublished 2022-12-01T06:44
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nc59bbf9fb7024d1d98c08a05fcefcc91
97 schema:url https://doi.org/10.1007/s13300-022-01218-y
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N0210fc234394457f94023aa3add238eb rdf:first sg:person.01121135113.11
102 rdf:rest N0d9270d7d58b46d4a9df2b7b8ba39590
103 N0d9270d7d58b46d4a9df2b7b8ba39590 rdf:first sg:person.07745622554.10
104 rdf:rest N92502ae385e4478aa17da9bbdd06fcd4
105 N158351eda93644699f9dae0898fbe490 schema:volumeNumber 13
106 rdf:type schema:PublicationVolume
107 N2d2ece0cf90e49c0b4bd2925876105c8 schema:issueNumber 3
108 rdf:type schema:PublicationIssue
109 N92502ae385e4478aa17da9bbdd06fcd4 rdf:first Nf15c2248df514534a048757a0b2eda6e
110 rdf:rest Ne837b8d3b4d2431bae381c2af7d38f34
111 N9fb1e70201554ecebff1ba89d155bff8 rdf:first sg:person.013423740504.43
112 rdf:rest N0210fc234394457f94023aa3add238eb
113 Nb5095dada8554f72a9360b4c33765fb4 schema:name pubmed_id
114 schema:value 35230650
115 rdf:type schema:PropertyValue
116 Nc59bbf9fb7024d1d98c08a05fcefcc91 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 Nd895bd8986df45fe8a047e6523e95f8c schema:name doi
119 schema:value 10.1007/s13300-022-01218-y
120 rdf:type schema:PropertyValue
121 Ne837b8d3b4d2431bae381c2af7d38f34 rdf:first sg:person.011233417104.69
122 rdf:rest rdf:nil
123 Nf15c2248df514534a048757a0b2eda6e schema:affiliation grid-institutes:grid.502754.1
124 schema:familyName Norgiolini
125 schema:givenName Roberto
126 rdf:type schema:Person
127 Nf64eb2f1642645df878c19bde04bbb38 schema:name dimensions_id
128 schema:value pub.1145925452
129 rdf:type schema:PropertyValue
130 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
131 schema:name Medical and Health Sciences
132 rdf:type schema:DefinedTerm
133 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
134 schema:name Clinical Sciences
135 rdf:type schema:DefinedTerm
136 sg:journal.1044057 schema:issn 1869-6953
137 1869-6961
138 schema:name Diabetes Therapy
139 schema:publisher Springer Nature
140 rdf:type schema:Periodical
141 sg:person.01121135113.11 schema:affiliation grid-institutes:grid.502754.1
142 schema:familyName Minarelli
143 schema:givenName Viviana
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121135113.11
145 rdf:type schema:Person
146 sg:person.011233417104.69 schema:affiliation grid-institutes:None
147 schema:familyName Del Sindaco
148 schema:givenName Paola
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011233417104.69
150 rdf:type schema:Person
151 sg:person.013423740504.43 schema:affiliation grid-institutes:None
152 schema:familyName Di Loreto
153 schema:givenName Chiara
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013423740504.43
155 rdf:type schema:Person
156 sg:person.07745622554.10 schema:affiliation grid-institutes:None
157 schema:familyName Nasini
158 schema:givenName Giovanni
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07745622554.10
160 rdf:type schema:Person
161 sg:pub.10.1007/s13300-020-00894-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1129709395
162 https://doi.org/10.1007/s13300-020-00894-y
163 rdf:type schema:CreativeWork
164 sg:pub.10.1007/s13300-020-00984-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1134130078
165 https://doi.org/10.1007/s13300-020-00984-x
166 rdf:type schema:CreativeWork
167 sg:pub.10.1007/s13300-021-01010-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135420761
168 https://doi.org/10.1007/s13300-021-01010-4
169 rdf:type schema:CreativeWork
170 sg:pub.10.1007/s13300-021-01015-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1135271828
171 https://doi.org/10.1007/s13300-021-01015-z
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/s13300-021-01053-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137050437
174 https://doi.org/10.1007/s13300-021-01053-7
175 rdf:type schema:CreativeWork
176 grid-institutes:None schema:alternateName Diabetes Clinic, USL Umbria 1, Castiglione del Lago Hospital District, Castiglione del Lago, Italy
177 Diabetes Clinic, USL Umbria 1, Perugia Territorial Health Structure, Perugia, Italy
178 schema:name Diabetes Clinic, USL Umbria 1, Castiglione del Lago Hospital District, Castiglione del Lago, Italy
179 Diabetes Clinic, USL Umbria 1, Perugia Territorial Health Structure, Perugia, Italy
180 rdf:type schema:Organization
181 grid-institutes:grid.502754.1 schema:alternateName Diabetes Clinic, USL Umbria 1, Città di Castello Hospital, Città di Castello, Italy
182 schema:name Diabetes Clinic, USL Umbria 1, Città di Castello Hospital, Città di Castello, Italy
183 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...